Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

TGF-beta can signal by means of Smad transcription factors, which are quintessential tumor suppressors that inhibit cell proliferation, and by means of Smad-independent mechanisms, which have been implicated in tumor progression. Although Smad mutations disable this tumor-suppressive pathway in certain cancers, breast cancer cells frequently evade the cytostatic action of TGF-beta while retaining Smad function. Through immunohistochemical analysis of human breast cancer bone metastases and functional imaging of the Smad pathway in a mouse xenograft model, we provide evidence for active Smad signaling in human and mouse bone-metastatic lesions. Genetic depletion experiments further demonstrate that Smad4 contributes to the formation of osteolytic bone metastases and is essential for the induction of IL-11, a gene implicated in bone metastasis in this mouse model system. Activator protein-1 is a key participant in Smad-dependent transcriptional activation of IL-11 and its overexpression in bone-metastatic cells. Our findings provide functional evidence for a switch of the Smad pathway, from tumor-suppressor to prometastatic, in the development of breast cancer bone metastasis.

[1]  G. Passeri,et al.  Interleukin-11: a new cytokine critical for osteoclast development. , 1994, The Journal of clinical investigation.

[2]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[3]  Masafumi Oshiro,et al.  Visualizing Gene Expression in Living Mammals Using a Bioluminescent Reporter , 1997, Photochemistry and photobiology.

[4]  Weiliang Tang,et al.  Transforming Growth Factor-β Stimulates Interleukin-11 Transcription via Complex Activating Protein-1-dependent Pathways* , 1998, The Journal of Biological Chemistry.

[5]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[6]  K. Miyazono,et al.  Interaction and Functional Cooperation of PEBP2/CBF with Smads , 1999, The Journal of Biological Chemistry.

[7]  A. Jakubowiak,et al.  Inhibition of the Transforming Growth Factor β1 Signaling Pathway by the AML1/ETO Leukemia-associated Fusion Protein* , 2000, The Journal of Biological Chemistry.

[8]  T. Grundström,et al.  Smad and AML Proteins Synergistically Confer Transforming Growth Factor β1 Responsiveness to Human Germ-line IgA Genes* , 2000, The Journal of Biological Chemistry.

[9]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[10]  C. Sotiriou,et al.  Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. , 2001, Cancer letters.

[11]  J. Massagué,et al.  Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[13]  H. Moses,et al.  Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. , 2001, Molecular biology of the cell.

[14]  S. Larson,et al.  Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. , 2001, Neoplasia.

[15]  A. Balmain,et al.  Metastasis is driven by sequential elevation of H-ras and Smad2 levels , 2002, Nature Cell Biology.

[16]  J. Chirgwin,et al.  Transforming Growth Factor-Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways * , 2002 .

[17]  S. Takeda,et al.  Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice* , 2002, The Journal of Biological Chemistry.

[18]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[19]  R. Tsien,et al.  A monomeric red fluorescent protein , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[21]  Shokei Kim,et al.  Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[22]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[23]  R. Cardiff,et al.  Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[25]  R. Blasberg,et al.  A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  L. Wakefield,et al.  Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. , 2003, Cancer research.

[27]  Carlos L. Arteaga,et al.  Targeting the TGFβ signaling network in human neoplasia , 2003 .

[28]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[29]  J. Massagué,et al.  A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. , 2003, Molecular cell.

[30]  L. Chodosh,et al.  Conditional Overexpression of Active Transforming Growth Factor β1 In vivo Accelerates Metastases of Transgenic Mammary Tumors , 2004, Cancer Research.

[31]  A. Tumber,et al.  Breast cancer cells induce osteoclast formation by stimulating host IL‐11 production and downregulating granulocyte/macrophage colony‐stimulating factor , 2004, International journal of cancer.

[32]  Vladimir Ponomarev,et al.  Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice , 2004, Cancer Research.

[33]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[34]  Ying E. Zhang,et al.  Smad-Binding Defective Mutant of Transforming Growth Factor β Type I Receptor Enhances Tumorigenesis but Suppresses Metastasis of Breast Cancer Cell Lines , 2004, Cancer Research.

[35]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[36]  W. Gerald,et al.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. , 2005, The Journal of clinical investigation.

[37]  G. Stein,et al.  Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.